New Review Maps Future Treatment Directions for Anti-NMDA Receptor Encephalitis
View StudyPlain-Language Summary
A Cell Press review in Trends in Molecular Medicine surveys emerging therapies for anti-NMDA receptor encephalitis, including IL-6 inhibitors and B cell-directed agents currently in randomized trials. The paper also highlights neurofilament light chain as a promising biomarker for identifying patients at risk of poor long-term outcomes.
Abstract
Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis is the most common autoimmune encephalitis, predominantly affecting young women and frequently associated with ovarian teratoma. Pathogenic NMDAR antibodies cause receptor internalization and synaptic dysfunction, producing a characteristic clinical syndrome including psychiatric symptoms, cognitive impairment, movement disorders, autonomic instability, and decreased consciousness.
Standard first-line therapy (corticosteroids, IVIG, plasma exchange) and second-line therapy (rituximab, cyclophosphamide) achieve favorable outcomes (mRS 0-2) in approximately 80% of patients, with immunotherapy initiation within 30 days of onset increasing from 50.1% to 72.5% in recent cohorts. Investigational approaches include IL-6 pathway inhibitors (satralizumab) and B cell/plasma cell-directed therapies in ongoing randomized controlled trials. Serum and CSF neurofilament light chain (NfL) at disease onset demonstrates utility in predicting poor long-term outcomes; the NEOS score combined with NfL improves prognostic accuracy beyond clinical variables alone.